Replimune Group’s (REPL) “Market Perform” Rating Reaffirmed at Leerink Partners

Leerink Partners restated their market perform rating on shares of Replimune Group (NASDAQ:REPL) in a report released on Monday morning, Marketbeat Ratings reports. The firm currently has a $2.00 price objective on the stock, down from their prior price objective of $11.00.

Several other analysts also recently issued reports on REPL. Piper Sandler downgraded Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a report on Friday. HC Wainwright reiterated a “sell” rating on shares of Replimune Group in a report on Monday. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Replimune Group in a report on Monday. Wedbush reiterated a “neutral” rating and issued a $2.00 price target (down from $19.00) on shares of Replimune Group in a report on Monday. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $2.00 price target (down from $13.00) on shares of Replimune Group in a report on Monday. Six equities research analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Reduce” and an average target price of $4.63.

Replimune Group Trading Down 64.3%

REPL stock opened at $1.70 on Monday. The company has a market cap of $140.37 million, a price-to-earnings ratio of -0.49 and a beta of 0.74. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33. The business has a fifty day simple moving average of $7.41 and a 200-day simple moving average of $7.94. Replimune Group has a 52 week low of $1.50 and a 52 week high of $13.24.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.08. On average, equities research analysts expect that Replimune Group will post -2.97 EPS for the current year.

Insider Buying and Selling

In related news, insider Christopher Sarchi sold 6,500 shares of the stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total value of $52,065.00. Following the completion of the transaction, the insider owned 151,588 shares of the company’s stock, valued at approximately $1,214,219.88. This represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of REPL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Replimune Group by 17.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock valued at $435,000 after purchasing an additional 6,653 shares during the last quarter. Millennium Management LLC grew its stake in Replimune Group by 2.8% in the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock worth $11,927,000 after purchasing an additional 33,574 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after purchasing an additional 119,145 shares in the last quarter. Rhumbline Advisers grew its stake in Replimune Group by 6.9% in the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock worth $948,000 after purchasing an additional 6,616 shares in the last quarter. Finally, Sei Investments Co. grew its stake in Replimune Group by 149.5% in the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock worth $283,000 after purchasing an additional 18,263 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group News Roundup

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Company response — Replimune’s executive chairman publicly called the FDA decision “unfair” and discussed next steps in a TV interview; management tone suggests they will contest or seek clarification with the agency. Replimune co-founder calls FDA rejection ‘unfair’
• Neutral Sentiment: Market mechanics — Trading on REPL was temporarily halted (LULD pause) during the sell-off as the market digested the CRL. (Intraday regulatory pause)
• Neutral Sentiment: Industry analysis — A PharmTech piece reviews lessons from the RP1 CRL for other developers; useful context but does not change Replimune’s immediate financials. What Pharma Developers Can Learn From RP1’s Rejection
• Negative Sentiment: Regulatory setback — The FDA issued a CRL for RP1’s Biologics License Application for advanced melanoma, delaying approval and forcing Replimune to address agency deficiencies before any potential approval. FDA Issues CRL to Replimune for RP1 BLA
• Negative Sentiment: Second CRL / program risk — Coverage notes this is a second CRL for RP1, increasing uncertainty about the regulatory path and timing for any approval or label; that uncertainty undermines near-term revenue and valuation expectations. Replimune Gets Second FDA CRL
• Negative Sentiment: Market reaction — Major outlets report REPL plunged to an all-time low on the news, with heavy trading and a dramatic drop in market value. Street sours on Replimune
• Negative Sentiment: Cost actions — Reports indicate Replimune is planning layoffs after the FDA decision, signaling management expects reduced near-term operating activity and is cutting burn. Replimune plans layoffs after FDA rejects cancer therapy
• Negative Sentiment: Analyst reaction — Multiple firms cut ratings and slashed price targets (downgrades and lower PTs from Jefferies, BMO, Wedbush, Leerink, JPMorgan, HC Wainwright, Piper and others), reflecting reduced probability of near-term upside. FDA Rejection Sparks Questions On Replimune Drug Approval Path

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.